Mylan launches generic version of Klor-Con

|About: Mylan Inc (MYL)|By:, SA News Editor

Mylan (NASDAQ:MYL) begins shipping its potassium chloride extended release tablets (8 mEq (600 mg) and 10 mEq (750 mg)), generic versions of Upsher-Smith's Klor-Con, for the treatment of patients with hypokalemia, with or without metabolic alkalosis, digitalis intoxication and hypokalemic familial periodic paralysis.

According to IMS Health, the U.S. market is ~$135M.